US3897549A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Herpes simplex type 2 virus vaccine and method of production and use
Assignee: Recherche et Industrie Therapeutiques
•
Filing: 1974-03-07
•
Granted: 1975-07-29
•
Expires: 1994-03-07
Abstract
Abstract The invention pertains to the preparation of temperaturesensitive and substantially non-pathogenic mutant strains of Herpes Simplex type 2 virus which are valuable for the preparation of vaccines, to the vaccines containing said temperature-sensitive mutant strains and to a new vaccination method against viral exanthermatous diseases.
Inventors
- 👤 Nathan Zygraich
- 👤 Constant Huygelen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 16:35
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/01; A; A61; A61K; A61K39/00; A61K39/12; A61K39/245; A61P; A61P31/00; A61P31/12; A61P31/20; A61P31/22; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16634; Y; Y10; Y10S; Y10S424/00; Y10S424/821
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
104 words
A VACCINATION METHOD BROADLY PROTECTIVE OF THE WHOLE VACCINATED ORGANISM AGAINST HERPES SIMPLEX TYPE 2, AN EXANTHEMATOUS VIRAL DISEASE, CONSISTING OF ADMINISTERING INTO THE UPPER RESPIRATORY TRACT, MUCOSA, OR SKIN OF A SUSCEPTIBL ORGANISM AN EFFECTIVE DOSE OF AT LEAST 103 TCID50, PROTECTIVE AGAINST REINFECTION AT WARMER SITES, OF A TEMPERATURE-SENSITIVE AND SUBSTANTIALLY NON-PATHOGENIC NITROUS ACID MUTANT STRAIN OF A HERPES SIMPLEX TYPE 2 VIRUS RESPONSIBLE FOR SAID EXANTHERMATOUS VIRAL DISEASE, SAID MUTANT CAPABLE OF MULTIPLYING AT SKIN TEMPERATURE AND IN THE MUCOSA OF THE UPPER RESPIRATORY TRACT BUT HAVING PARTICALLY OR COMPLETETELY INHIBITED REPLACATION IN THE LOWER RESPIRATORY TACT AND IN THE BODY.
Claim 2
Dependent Claim
104 words
A VACCINATION METHOD BROADLY PROTECTIVE OF THE WHOLE VACCINATED ORGANISM AGAINST HERPES SIMPLEX TYPE 2, AN EXANTHEMATOUS VIRAL DISEASE, CONSISTING OF ADMINISTERING INTO THE UPPER RESPIRATORY TRACT, MUCOSA, OR SKIN OF A SUSCEPTIBL ORGANISM AN EFFECTIVE DOSE OF AT LEAST 103 TCID50, PROTECTIVE AGAINST REINFECTION AT WARMER SITES, OF A TEMPERATURE-SENSITIVE AND SUBSTANTIALLY NON-PATHOGENIC NITROUS ACID MUTANT STRAIN OF A HERPES SIMPLEX TYPE 2 VIRUS RESPONSIBLE FOR SAID EXANTHERMATOUS VIRAL DISEASE, SAID MUTANT CAPABLE OF MULTIPLYING AT SKIN TEMPERATURE AND IN THE MUCOSA OF THE UPPER RESPIRATORY TRACT BUT HAVING PARTICALLY OR COMPLETETELY INHIBITED REPLACATION IN THE LOWER RESPIRATORY TACT AND IN THE BODY.
Claim 3
Dependent Claim
14 words
A method according to claim 1, in which the route of administration is intradermal.
Claim 4
Dependent Claim
23 words
A method according to claim 2, in which the route of administration is intradermal scarification and the dose is at least 104.5 TCID50.
Claim 5
Dependent Claim
36 words
A Herpes Simplex type 2 virus vaccine comprising as active ingredient at least 103 TCID50 of a nitrous acid mutant strain of Herpes Simplex type 2 virus strain according to claim 1 and a pharmaceutical diluent.
Claim 6
Dependent Claim
12 words
A vaccine according to claim 4, in which the vaccine is freeze-dried.
Claim 7
Dependent Claim
15 words
A vaccine according to claim 4, in which the dose is at least 104.5 TCID50.
References Cited (Backward Citations)
JPS4848621A
Cited
DE2215728A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-07-28 | 1979-01-27 | 1979-07-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-07-28 | 1983-01-27 | 1983-07-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-07-28 | 1987-01-27 | 1987-07-29 | $7700.00 | Window Closed / Lapsed |